4.6 Article

Developing New Drug Treatments in the Era of Network Medicine

期刊

CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 93, 期 1, 页码 26-28

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.207

关键词

-

资金

  1. National Institutes of Health (NIH) [HL113264, HL075478, HL105339, HL089856, HL083069, HL061795, HL048743, HL107192, HL070819, HL108630]
  2. NHLBI
  3. GlaxoSmithKline
  4. AstraZeneca
  5. Merck

向作者/读者索取更多资源

Although impressive advances have been made in determining the genetic and molecular causes of disease, treatment for many complex diseases remains inadequate. Despite compelling unmet medical needs and new insights into disease pathobiology, new drug approvals for complex diseases have stagnated. A new paradigm for drug development is needed, and key concepts from network medicine and systems pharmacology may be essential to this effort.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据